急性髓系白血病患儿体重指数、体重与身高的变化及其与结局的关联
在圣犹大儿童研究医院2002-2017年纳入AML02与AML08试验的227例儿童急性髓系白血病患者中,评估诊断时及治疗结束后5年内BMI、体重、身高Z评分变化及其与不良事件和结局的关联。治疗期间体重和身高Z评分显著下降,停疗5年后体重和BMI Z评分显著升高而身高Z评分仍显著低于基线;基线BMI与结局无关,较高体重Z评分与较低难治或复发疾病发生率及较高缓解期死亡率相关。
要点
- 治疗期间体重和身高Z评分显著下降,停疗5年后体重和BMI Z评分显著升高而身高Z评分仍低于基线。
- 移植受者身高Z评分从移植时-0.211进一步降至12个月后-0.617。
- 较高体重Z评分与较低难治或复发疾病发生率及较高缓解期死亡率相关。
核心结论
- 基线BMI类别和Z评分与结局无关,但较高体重Z评分与较低难治或复发疾病发生率及较高缓解期死亡率相关。
- 诱导治疗期间体重Z评分下降与后续治疗期间胃肠道、肝脏和感染毒性及缓解期死亡相关。
- 需要从诊断到停疗期间对体重变化和身材矮小进行多学科监测。
研究设计与样本
- 研究为在圣犹大儿童研究医院开展的队列分析,纳入2002-2017年AML02和AML08试验中227例儿童急性髓系白血病患者。
- 评估诊断时BMI、体重和身高Z评分,从诊断到停疗后5年的纵向变化,及其与不良事件和结局的关联。
主要发现
- 基线体重、身高和BMI中位Z评分分别为0.193、0.209和0.170。
- 治疗期间体重和身高Z评分显著下降,停疗时分别降至-0.038和-0.163(两者P < .001)。
- 停疗5年时体重和BMI Z评分显著升高至0.492(P = .003)和0.911(P < .001),身高Z评分仍显著低于基线为-0.066(P < .001)。
- 移植受者身高Z评分从移植时-0.211降至12个月后-0.617(P < .001)。
- 较高体重Z评分与较低难治或复发疾病发生率相关(HR 0.82;95%CI 0.67-0.99),与较高缓解期死亡发生率相关(HR 1.31;95%CI 1.01-1.70);诱导治疗期间体重Z评分下降与缓解期死亡相关(HR 2.66;95%CI 1.11-6.45)。
临床怎么用
- 作者认为需要从诊断到停疗期间对体重变化和身材矮小进行多学科监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Little is known about body composition changes in patients with acute myeloid leukemia (AML) during and after treatment or their associations with outcomes. Z-scores for body mass index (BMI), weight, and height at diagnosis, their longitudinal changes from diagnosis to 5 years off therapy, and their associations with adverse effects and outcomes were evaluated in 227 pediatric patients with AML enrolled in the AML02 and AML08 trials at St. Jude Children's Research Hospital between 2002-2017. The median Z-scores for baseline weight, height, and BMI were 0.193, 0.209, and 0.170, respectively, and those for weight and height decreased significantly during therapy to -0.038 and -0.163, respectively, at off-therapy (P < .001 for both). At 5 years off therapy, the Z-scores for weight and BMI had increased significantly to 0.492 (P = .003) and 0.911 (P < .001), respectively, whereas the height Z-score remained significantly lower at -0.066 (P < .001) compared with baseline. The height Z-score of transplant recipients decreased further from -0.211 at transplant to -0.617 12 months later (P < .001). Baseline BMI category and Z-score were not associated with outcomes, but higher weight Z-scores were associated with lower incidences of refractory or relapsed disease (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.67-0.99) and higher incidences of death in remission (HR, 1.31; 95% CI, 1.01-1.70). Furthermore, weight Z-score decrease during induction therapy was associated with gastrointestinal, hepatic, and infection toxicities during subsequent therapy and with death in remission (HR, 2.66; 95% CI, 1.11-6.45). Multidisciplinary monitoring for weight changes and short stature is required from diagnosis to the off-therapy period.
引用
- Iijima M, Stall M, Wang L, et al. Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. Blood Adv. 2022. PMID: 35196375. doi:10.1182/bloodadvances.2021006090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。